Programa de trasplantes de riñón

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study of Extracellular RNA Markers of Liver Disease and Cancer

   Jacksonville, Fla., Rochester, Minn.

   This study is being done to collect and store samples of blood from patients with liver disease for a research study to be able to find a new and better way to detect liver cancer.

2. Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

3. Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR is to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).

4. Exercise to Treat Frailty in Kidney Transplant Candidates

   Rochester, Minn.

   Frailty is a condition characterized by slowness, weakness, low physical activity, wasting, and exhaustion. Frailty increases the risk for adverse outcomes following transplant such as increased length of stay in the hospital, mortality, or graft function. No interventions for frailty are known for patients with renal disease, but exercise programs like pulmonary rehabilitation have been effective in improving frailty in patients with other diseases, such as lung disease. The goal of this study is to test whether exercise will also improve frailty among patients who are waiting for a kidney transplant and who are considered frail or pre-frail.

5. A Study To Confirm the Effectiveness and Safety of Terlipressin in Adults with Hepatorenal Syndrome Type 1

   Jacksonville, Fla.

   The purpose of this study is to confirm the effectiveness and safety of intravenous terlipressin in the treatment of adult patients who have hepatorenal syndrome (HRS) type 1.

6. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors

   Jacksonville, Fla.

   This study will collect and store samples of tissue and blood for current and future research studies on Liver and Biliary Tumors.

7. A Study to Evaluate the Effectiveness and Safety of Exenatide SR for Diabetes Prevention Following Kidney Transplantation

   Rochester, Minn.

   The purpose of this study is to compare the rate of progression from prediabetes at 4 months to frank diabetes at 12 months (as defined by increase in HbA1C or fasting BS to diabetic range based on the ADA criteria) after transplantation in kidney transplant recipients on Exenatide SR + SOC vs. standard-of-care alone.

   
    

8. Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients

   Rochester, Minn.

   The aim of this study is to determine the validity of two tests on bone marrow of sensitized kidney transplant recipients in order to better understand why these patients with antibodies against their donors are at a greater risk of rejection of their transplanted organs.

9. A Study to Develop a Database of Pancreas Transplant Recipients, to Form a Larger Cohort for Future Research

   Rochester, Minn.

   The purpose of this study is to form a database collection of pancreas transplant recipients, of a large enough size that further studies can be carried out. The data collected will be shared and received by all institutions.

10. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant

    Rochester, Minn.

    To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated rejection (of renal allograft) (AMR) in kidney transplant recipients as measured by the proportion of subjects with new or worsening transplant glomerulopathy (TG) at 6 months after treatment initiation.